Search Results - "Van den Anker, John N."

Current Use of mTOR Inhibitors for the Treatment of Subependymal Giant Cell Astrocytomas and Epilepsy in Patients with TSC by Jancic, Jasna, Duric, Vesna, Ivancevic, Nikola, Nikolic, Blazo, van den Anker, John N, Samardzic, Janko

“…The serine/threonine kinase mechanistic target of rapamycin (mTOR) is an important sensor of the cellular energy condition which, at the same time, represents…”
Get more information

Impact of Obesity on Drug Metabolism and Elimination in Adults and Children by Brill, Margreke J. E., Diepstraten, Jeroen, van Rongen, Anne, van Kralingen, Simone, van den Anker, John N., Knibbe, Catherijne A. J.

“…The prevalence of obesity in adults and children is rapidly increasing across the world. Several general (patho)physiological alterations associated with…”
Get full text

A critical appraisal of safety data on dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis by Katalinic, Alexander, Shulman, Lee P., Strauss, Jerome F., Garcia-Velasco, Juan A, Anker, John N. van den

“…No data support the suggestion that first-trimester dydrogesterone use increases the risk of fetal abnormalities; however, two low-quality retrospective…”
Get full text

Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir by Liu, Xiaomei I., Momper, Jeremiah D., Rakhmanina, Natella, den Anker, John N., Green, Dionna J., Burckart, Gilbert J., Best, Brookie M., Mirochnick, Mark, Capparelli, Edmund V., Dallmann, André

“…Pregnancy is associated with physiological changes that may impact drug pharmacokinetics (PK). The goals of this study were to build maternal‐fetal…”
Get full text

Pharmacokinetics of Intravenous Lorazepam in Pediatric Patients with and without Status Epilepticus by Chamberlain, James M., MD, Capparelli, Edmund V., PharmD, Brown, Kathleen M., MD, Vance, Cheryl W., MD, Lillis, Kathleen, MD, Mahajan, Prashant, MD, MPH, MBA, Lichenstein, Richard, MD, Stanley, Rachel M., MD, MHSA, Davis, Colleen O., MD, MPH, FAAP, FACEP, Gordon, Stephen, MD, Baren, Jill M., MD, MBE, FACEP, FAAP, van den Anker, John N., MD, PhD, FCP, FAAP

“…Objective To evaluate the single dose pharmacokinetics of an intravenous dose of lorazepam in pediatric patients treated for status epilepticus (SE) or with a…”
Get full text

Neonatal pain management: still in search for the Holy Grail by Allegaert, Karel, van den Anker, John N

“…Inadequate pain management but also inappropriate use of analgesics in early infancy has negative effects on neurodevelopmental outcome. As a consequence,…”
Get full text

Intravenous or Oral Acetaminophen for Analgesia After Cesarean Section: Exposure Drives Pain Relief by Mian, Paola, Dallmann, André, van den Anker, John N, Tibboel, Dick, Allegaert, Karel

Get full text

Approaches to Dose Finding in Neonates, Illustrating the Variability between Neonatal Drug Development Programs by Van den Anker, John N., McCune, Susan, Annaert, Pieter, Baer, Gerri R., Mulugeta, Yeruk, Abdelrahman, Ramy, Wu, Kunyi, Krudys, Kevin M., Fisher, Jeffrey, Slikker, William, Chen, Connie, Burckart, Gilbert J., Allegaert, Karel

“…Drug dosing in neonates should be based on integrated knowledge concerning the disease to be treated, the physiological characteristics of the neonate, and the…”
Get full text

A big thank you and a warm welcome by den Anker, John N.

Get full text

Neonatal Therapeutics: Time for a More Effective and Impactful Collaboration Between Neonatologists and Clinical Pharmacologists by den Anker, John N.

Get full text

Off-Label Use of Drugs in Children by NEVILLE, Kathleen A

“…The passage of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act has collectively resulted in an improvement in rational…”
Get full text

Therapeutic Drug Monitoring of Antimicrobial Drugs in Neonates: An Opinion Article by Touw, Daan J., van den Anker, John N.

“…Neonatal infections are associated with high morbidity and mortality rates. Optimal treatment of these infections requires knowledge of neonatal pharmacology…”
Get full text

The Vision for Expanding the Visibility of the Journal of Clinical Pharmacology: Meet the New Editor-in-Chief and the 3 New Associate Editors by van den Anker, John N, Arya, Vikram, Knibbe, Catherijne A J, Zhou, Honghui

Get full text

Progress in Drug Development–Pediatric Dose Selection: Workshop Summary by Wang, Jian, den Anker, John N., Burckart, Gilbert J.

“…The "Pediatric Dose Selection" workshop was held in October 2020 and sponsored by the U.S. Food and Drug Administration and the University of Maryland Center…”
Get full text

Adolescents and Drug Development: Commentary on a Dawning Paradigm Shift by Kearns, Gregory L., Anker, John N.

Get full text

Neonatal and Pediatric Dose Selection: Quo Vadis? by Burckart, Gilbert J., den Anker, John N.

Get full text

Use of inhaled steroids to prevent bronchopulmonary dysplasia: a matter of great debate by Samiee-Zafarghandy, Samira, van den Anker, John N

“…Correspondence to Dr Samira Samiee-Zafarghandy, Division of Neonatology, Department of Paediatrics, McMaster University, Hamilton ON L8S 4L8, Canada;…”
Get full text

Perinatal Clinical Pharmacology: Optimizing Pharmacotherapy for Pregnant Women, Their Fetuses and Infants by Allegaert, Karel, van den Anker, John N

Get more information

Disease-specific and glucocorticoid-responsive serum biomarkers for Duchenne Muscular Dystrophy by Hathout, Yetrib, Liang, Chen, Ogundele, Michael, Xu, Ganggang, Tawalbeh, Shefa M., Dang, Utkarsh J, Hoffman, Eric P., Gordish-Dressman, Heather, Conklin, Laurie S., van den Anker, John N., Clemens, Paula R., Mah, Jean K., Henricson, Erik, McDonald, Craig

“…Extensive biomarker discoveries for DMD have occurred in the past 7 years, and a vast array of these biomarkers were confirmed in independent cohorts and…”
Get full text

Pediatric Ontogeny: Moving From Translational Science to Drug Development by Burckart, Gilbert J., den Anker, John N.

Get full text